nelarabine
nelarabine: developed by 1 company · 3 clinical trials tracked · 1 FDA decision.
nelarabine evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could nelarabine → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) | Approved |
| NEXUS BIOPHARMA INC (NEXS) | Approved |
Clinical Trials (3)
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Primary endpoint: Minimal residual disease (MRD)-negativity rate in patients with T cell acute lymphoblastic leukemia
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Primary endpoint: Event-free survival of ALL patients (EFS)
FDA Decisions1 records
Frequently asked questions
Who is developing nelarabine?
nelarabine is being developed by NEXUS BIOPHARMA INC.
How many clinical trials involve nelarabine?
BioSniper tracks 3 clinical trials involving nelarabine.
What is nelarabine's latest FDA decision?
The most recent tracked FDA decision for nelarabine is Approval for 1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphom, dated June 2, 2023.